(00:32) 
 Would you mind telling our listeners a little about yourself and your background?

(01:16)
 This evaluation is about CIDP — chronic inflammatory demyelinating polyneuropathy, correct?

(02:16)
 Can you give us an overview of what the CIDP evaluation will consist of?

(04:38)
 Our standalone test for neurofascin-155 won't change, but will be rolled into this new test along with contactin-1, correct?

(06:41)
 This is a very rare disease with subtle clues, so does it make logical sense to pair these two antibodies?

(08:07)
 Why did we choose a cell-binding assay over a western blot or other methodology? Is there a reason why contactin-1 is better on CBA methodology?

(09:40)
 Can you elaborate on what this phenotype-specific approach means for neurologists, and how it makes their ordering easier?

(11:14)
 Even though it's hard to determine exactly what test to order for these patients, testing too broadly can just add to the confusion. Is a narrowed evaluation that answers specific questions more helpful?

(14:42)
 Can you give us any clues as to when a physician shouldn't order this test because it's unlikely to be positive?

(15:51)
 How does this test drive patient care? A lot of these patients are therapy refractory. What would be the second- or third-level treatment? Is there any oncological association with antibody positivity?

(18:44)
 Are there any alternative options for diagnostic answers for this challenging patient population?

(20:44)
 What is the key takeaway? What excites you most about this new test launch?